Search results
Results From The WOW.Com Content Network
Cryoprecipitate, also called cryo for short, or Cryoprecipitate Antihemophilic factor (AHF), is a frozen blood product prepared from blood plasma. [1] To create cryoprecipitate, Plasma is slowly thawed to 1–6 °C. A cold-insoluble precipitate is formed, which is collected by centrifugation, resuspended in a small amount of residual plasma ...
The Cohn process was a major development in the field of blood fractionation. It has several practical uses in treating diseases such as hepatitis and polio. It was most useful during the Second World War where soldiers recovered at a faster rate because of the transfusions with albumin. The Cohn Process has been modified over the years as seen ...
The term cryosupernatant (also called cryo-poor plasma, cryoprecipitate depleted, cryoprecipitate reduced plasma) refers to plasma from which the cryoprecipitate has been removed. It is used to treat thrombocytopenic purpura .
In pharmacokinetics, the rate of infusion (or dosing rate) refers not just to the rate at which a drug is administered, but the desired rate at which a drug should be administered to achieve a steady state of a fixed dose which has been demonstrated to be therapeutically effective. Abbreviations include K in, [1] K 0, [2] or R 0.
There are two main types of volume expanders: crystalloids and colloids. Crystalloids are aqueous solutions of mineral salts or other water-soluble molecules. Colloids contain larger insoluble molecules, such as gelatin; blood itself is a colloid.
Oral administration of a liquid. In pharmacology and toxicology, a route of administration is the way by which a drug, fluid, poison, or other substance is taken into the body. [1] Routes of administration are generally classified by the location at which the substance is applied. Common examples include oral and intravenous administration ...
Prothrombin complex concentrate (PCC), also known as factor IX complex, sold under the brand name Kcentra among others, is a combination medication made up of blood clotting factors II, IX, and X [9] (3-factor PCC) or, when also containing factor VII as does Kcentra, 4-factor PCC. [10]
In current state of the art, early embryos having undergone cryopreservation implant at the same rate as equivalent fresh counterparts. [2] The outcome from using cryopreserved embryos has uniformly been positive with no increase in birth defects or development abnormalities, [3] [8] also between fresh versus frozen eggs used for intracytoplasmic sperm injection (ICSI). [9]